Resonance Health Limited has released its half-year report for the period ending 31 December 2025. The company reported a 53% increase in revenues to $7,975,096 and a 241% increase in profit after tax to $1,466,049 compared to the same period in 2024. The profit for the Group includes an income tax benefit of $561,343 due to Research and Development tax incentives.

The company's net tangible assets per ordinary security also improved, with current tangible assets increasing to 0.64 cents and overall tangible assets per ordinary security improving to 0.06 cents.

The financial statements were subject to a review by auditors HLB Mann Judd, and their independence declaration affirmed the accuracy and compliance of the financial report. The Directors' report highlighted the company's core business in medical imaging, its successful revenue growth, and the acquisition of TrialsWest Pty Ltd to expand its clinical trial services.

Investors are encouraged to review the detailed financial statements attached to the report for further insights into the company's performance and future prospects. Any questions regarding the report can be directed to the company's website or investor relations team.